Synbio: The Next Big Thing in Biotech

Trading the Next Phase of COVID-19 Variants

By

|

More than a year after the start of the COVID-19 pandemic, new variants of the disease pose a threat to those unvaccinated—which is more than 70% of the world. Few would have predicted that the world would still be grappling with the COVID-19 pandemic during the summer of 2021. Yet here we are. And unfortunately, … Continued

10 Charts That Define 2020’s Trading and What That Means for 2021 (Yes, There Is a Tesla Chart)

By

|

The 2020 trading year saw record volatility, record highs, record lows, and everything in between—as illustrated in the charts below. From a trading and investment perspective, 2020 has been one of the most memorable in history.  Today’s post represents a year in review in chart form—ideal for any market participant reflecting on the year that … Continued

Remdesivir: Confidence or Confusion?

By

|

Critical COVID-19 Treatment Update The global effort to discover safe and effective treatments for COVID-19 suffered a significant setback late last week when the World Health Organization (WHO) released its assessment of Remdesivir—a drug previously authorized in the United States for emergency use—suggesting that the drug provides little benefit for severely ill COVID-19 patients. The … Continued

Vaccine Trial Results Could Be the ‘October Surprise’

By

|

VIX futures indicate an uptick in market volatility in October/November, and not just because of the U.S. presidential election. There’s another event—with arguably even more gravity—set to hit the markets at about that same time: Phase 3 clinical results from a front-running COVID-19 vaccine candidate, Pfizer et al. The thing is, the stock market has … Continued

AstraZeneca Vaccine Snag Casts Shadow Over Market Rally

By

|

With millions of lives and livelihoods hanging in the balance, the need for a safe and effective Covid-19 vaccine is red-lining. Unfortunately, near-term hopes for a game-saving vaccine took a big hit on Sept. 8 when AstraZeneca (AZN) announced the company was temporarily pausing its Phase 3 coronavirus vaccine trials. This development is especially deflating … Continued